Zacharon Pharmaceuticals Inc.
Zacharon Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing a new class of human therapeutics which target the biosynthesis of glycans. Zacharon was incorporated in 2004 and has received initial funding through NIH grants and individual investors. Recently, Zacharon received Series A financing from Avalon Ventures, a long-standing San Diego-based venture capital firm with a focus on early stage life science companies. With this strong financial backing and innovative drug discovery platform in place, Zacharon is discovering and developing an entirely new class of human therapeutics targeting a range of diseases.
